$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000071913523000047 Filed on August 11, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$11.98M	$13.57M
YoY Change	31.4%	31.84%
Cost Of Revenue	$3.998M	$4.290M
YoY Change	19.09%	27.0%
Gross Profit	$7.978M	$9.279M
YoY Change	38.58%	34.21%
Gross Profit Margin	66.62%	68.38%
Selling, General & Admin	$4.841M	$5.378M
YoY Change	3.64%	18.48%
% of Gross Profit	60.68%	57.96%
Research & Development	$1.276M	$1.199M
YoY Change	20.26%	12.06%
% of Gross Profit	15.99%	12.92%
Depreciation & Amortization	$190.0K	$151.0K
YoY Change	-12.04%	-38.87%
% of Gross Profit	2.38%	1.63%
Operating Expenses	$12.62M	$13.21M
YoY Change	9.32%	2.45%
Operating Profit	-$4.637M	-$1.235M
YoY Change	-19.8%	-79.33%
Interest Expense	$585.0K	$543.0K
YoY Change	58400.0%	18000.0%
% of Operating Profit
Other Income/Expense, Net	-$356.0K	$282.0K
YoY Change	-1062.16%	-54.66%
Pretax Income	-$4.993M	-$953.0K
YoY Change	-13.09%	-82.2%
Income Tax	-$318.0K	$66.00K
% Of Pretax Income
Net Earnings	-$4.629M	-$994.0K
YoY Change	-19.69%	-81.68%
Net Earnings / Revenue	-38.65%	-7.33%
Basic Earnings Per Share	-$0.13	-$0.03
Diluted Earnings Per Share	-$0.13	-$0.03
COMMON SHARES
Basic Shares Outstanding	34.64M shares	34.60M shares
Diluted Shares Outstanding	34.64M shares	34.60M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.10M	$18.48M
YoY Change	48.99%	-7.9%
Cash & Equivalents	$22.10M	$18.50M
Short-Term Investments
Other Short-Term Assets	$3.500M	$3.100M
YoY Change	26.17%	11.91%
Inventory	$11.29M	$11.17M
Prepaid Expenses
Receivables	$12.65M	$12.07M
Other Receivables	$596.0K	$315.0K
Total Short-Term Assets	$50.15M	$52.89M
YoY Change	8.3%	4.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.093M	$2.118M
YoY Change	-69.27%	-69.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.855M	$1.908M
YoY Change	48.04%	50.35%
Total Long-Term Assets	$9.296M	$9.544M
YoY Change	3.74%	6.68%
TOTAL ASSETS
Total Short-Term Assets	$50.15M	$52.89M
Total Long-Term Assets	$9.296M	$9.544M
Total Assets	$59.45M	$62.43M
YoY Change	7.56%	4.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.050M	$2.658M
YoY Change	-0.97%	2.74%
Accrued Expenses	$7.500M	$7.009M
YoY Change	26.84%	19.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$8.892M
YoY Change	-100.0%	10361.18%
Total Short-Term Liabilities	$10.29M	$19.03M
YoY Change	-8.04%	67.63%
LONG-TERM LIABILITIES
Long-Term Debt	$9.009M	$63.00K
YoY Change	11450.0%	-32.26%
Other Long-Term Liabilities	$181.0K	$185.0K
YoY Change	36.09%	30.28%
Total Long-Term Liabilities	$9.190M	$185.0K
YoY Change	6809.77%	30.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.29M	$19.03M
Total Long-Term Liabilities	$9.190M	$185.0K
Total Liabilities	$25.86M	$25.70M
YoY Change	98.15%	93.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.84M	-$40.21M
YoY Change	51.05%	68.1%
Common Stock	$35.00K	$35.00K
YoY Change	0.0%	2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$33.35M	$36.60M
YoY Change
Total Liabilities & Shareholders Equity	$59.45M	$62.43M
YoY Change	7.56%	4.97%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$4.629M	-$994.0K
YoY Change	-19.69%	-81.68%
Depreciation, Depletion And Amortization	$190.0K	$151.0K
YoY Change	-12.04%	-38.87%
Cash From Operating Activities	$3.690M	-$4.852M
YoY Change	-168.84%	-17.37%
INVESTING ACTIVITIES
Capital Expenditures	$170.0K	$156.0K
YoY Change	-190.43%	-138.9%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$7.267M
YoY Change
Cash From Investing Activities	-$170.0K	$7.111M
YoY Change	-9.57%	-1873.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	160.0K	46.00K
YoY Change	25.98%	2200.0%
NET CHANGE
Cash From Operating Activities	3.690M	-4.852M
Cash From Investing Activities	-170.0K	7.111M
Cash From Financing Activities	160.0K	46.00K
Net Change In Cash	3.680M	2.305M
YoY Change	-167.88%	-136.76%
FREE CASH FLOW
Cash From Operating Activities	$3.690M	-$4.852M
Capital Expenditures	$170.0K	$156.0K
Free Cash Flow	$3.520M	-$5.008M
YoY Change	-168.06%	-8.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	8892000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	19029000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11850000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	56000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1714000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-5450000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	46163000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36214000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	56000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1482000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1019000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36733000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54009000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	208000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3364000	usd
	us-gaap	Profit Loss ProfitLoss	-11418000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	46163000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37793000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	56000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2849000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	586000	usd
	us-gaap	Profit Loss ProfitLoss	-4551000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36733000	usd
	us-gaap	Profit Loss ProfitLoss	-4551000	usd
	us-gaap	Profit Loss ProfitLoss	-11418000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	354000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	472000	usd
	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	178000	usd
	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	139000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2692000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-47000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2849000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3364000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	55000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	284000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	209000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
	apyx	Non Cash Lease Expense NonCashLeaseExpense	22000	usd
	apyx	Non Cash Lease Expense NonCashLeaseExpense	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1441000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2236000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	57000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	549000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	207000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-534000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3187000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-26000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	33000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1960000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1811000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6733000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10390000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	266000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	680000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7267000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7001000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-680000	usd
	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	56000	usd
	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	208000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9289000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1754000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	586000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	19000	usd
	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	108000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8158000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-139000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8287000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10807000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10192000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30870000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18479000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20063000	usd
	us-gaap	Interest Paid Net InterestPaidNet	431000	usd
	us-gaap	Interest Paid Net InterestPaidNet	11000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	227000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	8000	usd
	apyx	Capitalization Of Lease Non Cash CapitalizationOfLeaseNonCash	4917000	usd
	apyx	Capitalization Of Lease Non Cash CapitalizationOfLeaseNonCash	0	usd
	apyx	Capitalization Of Lease Execution CapitalizationOfLeaseExecution	0	usd
	apyx	Capitalization Of Lease Execution CapitalizationOfLeaseExecution	600000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	103000	usd
CY2018	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	97000000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-23600000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20300000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6800000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6700000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18500000	usd
CY2023Q2	apyx	Debt Instrument Covenant Cash And Cash Equivalents Balance DebtInstrumentCovenantCashAndCashEquivalentsBalance	10000000	usd
CY2023Q1	apyx	Sale Leaseback Purchase Agreement SaleLeasebackPurchaseAgreement	7650000	usd
CY2023Q2	us-gaap	Sale Leaseback Transaction Lease Term SaleLeasebackTransactionLeaseTerm	P10Y
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	200000	usd
CY2023Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.14
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	4663000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4979000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	2559000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2160000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4524000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5115000	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	11746000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	12254000	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	579000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	457000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	11167000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	11797000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5104000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11295000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3530000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5041000	usd
CY2023Q2	apyx	Property Plant And Equipment In Service PropertyPlantAndEquipmentInService	1574000	usd
CY2022Q4	apyx	Property Plant And Equipment In Service PropertyPlantAndEquipmentInService	6254000	usd
CY2023Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	544000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	507000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2118000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6761000	usd
CY2023Q1	apyx	Sale Leaseback Purchase Agreement SaleLeasebackPurchaseAgreement	7650000	usd
CY2023Q2	us-gaap	Sale Leaseback Transaction Lease Term SaleLeasebackTransactionLeaseTerm	P10Y
CY2023Q2	apyx	Sale Leaseback Net Cash Proceeds SaleLeasebackNetCashProceeds	6600000	usd
CY2023Q2	apyx	Sale Leaseback Security Deposit Withheld SaleLeasebackSecurityDepositWithheld	600000	usd
CY2023Q2	apyx	Sale Leaseback Security Deposit Equal To Annual Rent SaleLeasebackSecurityDepositEqualToAnnualRent	P1Y
CY2023Q2	us-gaap	Sale And Leaseback Transaction Gain Loss Net SaleAndLeasebackTransactionGainLossNet	2700000	usd
	us-gaap	Sale And Leaseback Transaction Gain Loss Net SaleAndLeasebackTransactionGainLossNet	2700000	usd
CY2023Q1	apyx	Sale Leaseback Term Of Lease SaleLeasebackTermOfLease	P10Y
CY2023Q1	apyx	Sale Leaseback Renewal Term SaleLeasebackRenewalTerm	P5Y
CY2023Q1	apyx	Sale Leaseback Annual Rent Payment SaleLeasebackAnnualRentPayment	619500	usd
CY2023Q1	apyx	Sale Leaseback Annual Rent Increase SaleLeasebackAnnualRentIncrease	0.04
CY2023Q1	apyx	Sale Leaseback Management Fee On Rent Payment SaleLeasebackManagementFeeOnRentPayment	0.03
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0836
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0254
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	417000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	777000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	803000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	830000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	858000	usd
CY2023Q2	apyx	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	4516000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8201000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2771000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5430000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	337000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5093000	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	636000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	563000	usd
CY2023Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1029000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	0	usd
CY2023Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1227000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	847000	usd
CY2023Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	387000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	391000	usd
CY2023Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1808000	usd
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1825000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	639000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	901000	usd
CY2023Q2	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	0	usd
CY2022Q4	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	345000	usd
CY2023Q2	apyx	Short Term Contract Liabilities ShortTermContractLiabilities	442000	usd
CY2022Q4	apyx	Short Term Contract Liabilities ShortTermContractLiabilities	853000	usd
CY2023Q2	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	0	usd
CY2022Q4	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	2079000	usd
CY2023Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	241000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	245000	usd
CY2023Q2	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	705000	usd
CY2022Q4	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	879000	usd
CY2023Q2	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7114000	usd
CY2022Q4	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8928000	usd
CY2023Q1	apyx	Debt Instrument Covenant Twelve Month Net Revenue Target Year One DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne	49000000	usd
CY2023Q1	apyx	Debt Instrument Covenant Twelve Month Net Revenue Target Year Two DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo	60000000	usd
CY2023Q1	apyx	Debt Instrument Covenant Twelve Month Net Revenue Target Year Three DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree	70000000	usd
CY2023Q1	apyx	Debt Instrument Covenant Cash And Cash Equivalents Balance DebtInstrumentCovenantCashAndCashEquivalentsBalance	10000000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	250000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.40
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P10Y
CY2023Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	1800000	usd
CY2023Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	450000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	658000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	8892000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2778000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3333000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3333000	usd
CY2023Q2	apyx	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	556000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	usd
CY2021Q4	apyx	Noncontrolling Interest Required Capital Contribution NoncontrollingInterestRequiredCapitalContribution	357000	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	203000	usd
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	154000	usd
CY2023Q2	apyx	Noncontrolling Interest Required Capital Contribution NoncontrollingInterestRequiredCapitalContribution	255000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-994000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-994000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5426000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5426000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4477000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4477000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11371000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11371000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34603000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34603000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34464000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34464000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34447000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34447000	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1482000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2849000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1714000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3364000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6520444	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1408865	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.50
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	35000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	194225	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.11
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7700084	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.27
CY2023Q2	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	4305	shares
CY2022Q2	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	14013	shares
CY2023Q2	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	5695	shares
CY2022Q2	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	19987	shares
	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	4305	shares
	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	36667	shares
	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	5695	shares
	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	39000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.858
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	96000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.069
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.018
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2201000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	166000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.326
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.015
CY2023Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	2100000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	250000	usd
CY2023Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	-250000	usd
CY2023Q2	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	-250000	usd
CY2023Q2	us-gaap	Purchase Obligation PurchaseObligation	3300000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13569000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1235000	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	179000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	543000	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	646000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10292000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5976000	usd
CY2022Q2	us-gaap	Interest Income Operating InterestIncomeOperating	18000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	3000	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	607000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	96000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25711000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6846000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	230000	usd
	us-gaap	Interest Expense InterestExpense	777000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	641000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2201000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22785000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11847000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	20000	usd
	us-gaap	Interest Expense InterestExpense	11000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	586000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	166000	usd
CY2023Q2	apyx	Total Revenue Percent TotalRevenuePercent	0.253
	apyx	Total Revenue Percent TotalRevenuePercent	0.261
CY2022Q2	apyx	Total Revenue Percent TotalRevenuePercent	0.228
	apyx	Total Revenue Percent TotalRevenuePercent	0.320
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13569000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10292000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25711000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22785000	usd

Files In Submission

Name	View Source	Status
apyx-20230630_lab.xml	Edgar Link	unprocessable
0000719135-23-000047-index-headers.html	Edgar Link	pending
0000719135-23-000047-index.html	Edgar Link	pending
0000719135-23-000047.txt	Edgar Link	pending
0000719135-23-000047-xbrl.zip	Edgar Link	pending
a2023q210-kexhibit311.htm	Edgar Link	pending
a2023q210-kexhibit312.htm	Edgar Link	pending
a2023q210-kexhibit322.htm	Edgar Link	pending
a2023q210-qexhibit321.htm	Edgar Link	pending
apyx-20230630.htm	Edgar Link	pending
apyx-20230630.xsd	Edgar Link	pending
apyx-20230630_g1.jpg	Edgar Link	pending
apyx-20230630_cal.xml	Edgar Link	unprocessable
apyx-20230630_def.xml	Edgar Link	unprocessable
apyx-20230630_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
apyx-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2023 Q3 Form 10-Q Financial Statement

#000071913523000047 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2023 Q3 Form 10-Q Financial Statement

#000071913523000047 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx